Ola Grimsholm

Dr. Ola Grimsholm

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SBSiggeir Fannar Brynjolfsson
Siggeir Fannar Brynjolfsson
LBLinn Persson Berg
Linn Persson Berg
TETeresa Olsen Ekerhult
Teresa Olsen Ekerhult
IRInga Rimkute
Inga Rimkute
MWMary-Jo Wick
Mary-Jo Wick
OGOla Grimsholm
Ola Grimsholm
Even though more than 30 years have passed since the eradication of smallpox, high titers of smallpox-specific antibodies are still detected in the blood of subjects vaccinated in childhood. In fact, smallpox-specific antibody levels are maintained in serum for more than 70 years. The generation of life-long immunity against infectious diseases such as smallpox and measles has been thoroughly documented. Although the mechanisms behind high persisting antibody titers in the absence of the causative agent are still unclear, long lived plasma cells (LLPCs) play an important role. Most of the current knowledge on LLPCs is based on experiments performed in mouse models, although the amount of data derived from human studies is increasing. As the results from mouse models are often directly extrapolated to humans, it is important to keep in mind that there are differences. These are not only the obvious such as the life span but there are also anatomical differences, for instance the adiposity of the bone marrow (BM) where LLPCs reside. Whether these differences have an effect on the function of the immune system, and in particular on LLPCs, are still unknown. In this review, we will briefly discuss current knowledge of LLPCs, comparing mice and humans.

13 May 2016 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
KTKatrin Thorarinsdottir
Katrin Thorarinsdottir
ACAlessandro Camponeschi
Alessandro Camponeschi
NCNicola Cavallini
Nicola Cavallini
OGOla Grimsholm
Ola Grimsholm
LJLennart Jacobsson
Lennart Jacobsson
IMInga‐Lill Mårtensson
Inga‐Lill Mårtensson

19 February 2023 in Advanced Science
Verified
Journal Article
Open access
Nawaz MuhammadNawaz Muhammad
Nawaz Muhammad
SHSepideh Heydarkhan‐Hagvall
Sepideh Heydarkhan‐Hagvall
BTBenyapa Tangruksa
Benyapa Tangruksa
HGHernán González‐King Garibotti
Hernán González‐King Garibotti
YJYujia Jing
Yujia Jing
Hadi ValadiHadi Valadi
Hadi Valadi
Lipid nanoparticles (LNPs) are currently used to transport functional mRNAs, such as COVID‐19 mRNA vaccines. The delivery of angiogenic molecules, such as therapeutic VEGF‐A mRNA, to ischemic tissues for producing new blood vessels is an emerging strategy for the treatment of cardiovascular diseases. Here, the authors deliver VEGF‐A mRNA via LNPs and study stoichiometric quantification of their uptake kinetics and how the transport of exogenous LNP‐mRNAs between cells is functionally extended by cells’ own vehicles called extracellular vesicles (EVs). The results show that cellular uptake of LNPs and their mRNA molecules occurs quickly, and that the translation of exogenously delivered mRNA begins immediately. Following the VEGF‐A mRNA delivery to cells via LNPs, a fraction of internalized VEGF‐A mRNA is secreted via EVs. The overexpressed VEGF‐A mRNA is detected in EVs secreted from three different cell types. Additionally, RNA‐Seq analysis reveals that as cells’ response to LNP‐VEGF‐A mRNA treatment, several overexpressed proangiogenic transcripts are packaged into EVs. EVs are further deployed to deliver VEGF‐A mRNA in vitro and in vivo. Upon equal amount of VEGF‐A mRNA delivery via three EV types or LNPs in vitro, EVs from cardiac progenitor cells are the most efficient in promoting angiogenesis per amount of VEGF‐A protein produced. Intravenous administration of luciferase mRNA shows that EVs could distribute translatable mRNA to different organs with the highest amounts of luciferase detected in the liver. Direct injections of VEGF‐A mRNA (via EVs or LNPs) into mice heart result in locally produced VEGF‐A protein without spillover to liver and circulation. In addition, EVs from cardiac progenitor cells cause minimal production of inflammatory cytokines in cardiac tissue compared with all other treatment types. Collectively, the data demonstrate that LNPs transform EVs as functional extensions to distribute therapeutic mRNA between cells, where EVs deliver this mRNA differently than LNPs.

1 November 2016 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
EMEmiliano Marasco
Emiliano Marasco
CFChiara Farroni
Chiara Farroni
SCSimona Cascioli
Simona Cascioli
VMValentina Marcellini
Valentina Marcellini
MSMarco Scarsella
Marco Scarsella
RCRita Carsetti
Rita Carsetti
Around 65% of primary immunodeficiencies are antibody deficiencies. Functional tests are useful tools to study B‐cell functions in vitro. However, no accepted guidelines for performing and evaluating functional tests have been issued yet. Here, we report our experience on the study of B‐cell functions in infancy and throughout childhood. We show that T‐independent stimulation with CpG measures proliferation and differentiation potential of memory B cells. Switched memory B cells respond better than IgM memory B cells. On the other hand, CD40L, a T‐dependent stimulus, does not induce plasma cell differentiation, but causes proliferation of naïve and memory B cells. During childhood, the production of plasmablasts in response to CpG increases with age mirroring the development of memory B cells. The response to CD40L does not change with age. In patients with selective IgA deficiency (SIgAD), we observed that switched memory B cells are reduced due to the absence of IgA memory B cells. In agreement, IgA plasma cells are not generated in response to CpG. Unexpectedly, B cells from SIgAD patients show a reduced proliferative response to CD40L. Our results demonstrate that functional tests are an important tool to assess the functions of the humoral immune system.

24 April 2010 in FEBS Letters
Verified
Journal Article
Closed access
IMInga-Lill Mårtensson
Inga-Lill Mårtensson
NANina Almqvist
Nina Almqvist
OGOla Grimsholm
Ola Grimsholm
ABAngelina I. Bernardi
Angelina I. Bernardi

12 December 2022 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
OGOla Grimsholm
Ola Grimsholm
Immunological memory protects the human body from re-infection with an earlier recognized pathogen. This memory comprises the durable serum antibody titres provided by long-lived plasma cells and the memory T and B cells with help from other cells. Memory B cells are the main precursor cells for new plasma cells during a secondary infection. Their formation starts very early in life, and they continue to form and undergo refinements throughout our lifetime. While the heterogeneity of the human memory B-cell pool is still poorly understood, specific cellular surface markers define most of the cell subpopulations. CD27 is one of the most commonly used markers to define human memory B cells. In addition, there are molecular markers, such as somatic mutations in the immunoglobulin heavy and light chains and isotype switching to, for example, IgG. Although not every memory B cell undergoes somatic hypermutation or isotype switching, most of them express these molecular traits in adulthood. In this review, I will focus on the most recent knowledge regarding CD27+ human memory B cells in health and disease, and describe how Ig sequencing can be used as a tool to decipher the evolutionary pathways of these cells.